Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with moder...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Michael J. Cork, Benjamin Lockshin, Andreas Pinter, Zhen Chen, Brad Shumel, Randy Prescilla
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Medical Journals Sweden 2024-02-01
سلاسل:	Acta Dermato-Venereologica
الموضوعات:	Atopic dermatitis eczema dupilumab infants paediatrics quality of life
الوصول للمادة أونلاين:	https://medicaljournalssweden.se/actadv/article/view/13467
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!